Aspirin bleeding in perspective

Quality in Primary Care

Volumn 19, Issue 4, 2011, Pages 251-253

  Morgan, Gareth ^a   Elwood, Peter ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Aspirin; Bleeding; Bowel cancer; General practice; Primary care; Vascular events

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT;

ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; HUMAN; RISK ASSESSMENT;

ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; ASPIRIN; CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; HEMORRHAGE; HUMANS; RISK ASSESSMENT;

EID: 80052693956     PISSN: 14791072     EISSN: 14791064     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet 2009;373: 1849-60.
2. Morgan GP. Ethical considerations in relation to aspirin prophylaxis. Quality in Primary Care 2008;6:433-40.
3. Zaninelli A, Kaufholz C and Schwappach D. Physicians' attitudes toward post-MI aspirin prophylaxis: findings from an online questionnaire in Europe and Latin America. Postgraduate Medicine 2009; 121:44-53.
4. Elwood P, Hughes J, Morgan GP, Brown G and Longley M. A survey of aspirin prophylaxis in Wales. Quality in Primary Care 2005; 119:734-7.
5. Baigent C. Aspirin for all over 50? British Medical Journal 2005;330:1442-3.
6. Barnett H, Burrill P and Iheanacho I. Don't use aspirin for primary prevention of cardiovascular disease. British Medical Journal 2010;340:c 1805.
7. Rothwell PM, Wilson W, Elwin C-E et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. The Lancet 2010;376:1741-50.
8. Rothwell PM, Coull AJ, Silver LE et al. Population-based study of event-rate, incidence, case-fatality and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). The Lancet 2005;366:1773-83. (Pubitemid 41642641)
9. Center MM, Jemal A, Smith R and Ward E. Worldwide variation in colorectal cancer. CA: a Cancer Journal for Clinicians 2009;59:366-78.
10. Luengo-Fernandez R, Gray AM and Rothwell PM. Population-based study of determinants of initial secondary care costs of acute stroke in the UK. Stroke 2006;37:2579-87. (Pubitemid 44454682)
11. Herrett E, Smeeth L, Walker L and Weston C. The Myocardial Infarction National Audit Project (MINAP). Heart 2010;96:1264-7.
12. Burt RW. Colorectal cancer screening. Current Opinion in Gastroenterology 2010;26:466-70.
13. Griffiths C, Rooney C and Brock A. Leading causes of death in England and Wales: how should we group causes? Health Statistics Quarterly 2005;28:6-17.
14. Hernández-Dias S and Rodriguez LAG. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiological studies. Journal of Clinical Epidemiology 2002;55:157-63. (Pubitemid 34051529)
15. Lanas A, Garcia-Rodriguez LA, Polo-Tomás M et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. American Journal of Gastroenterology 2009; 104:1633-41.Epub5May2009.
16. Sorensen HT, Mellemkjaer L and Blot WJ. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. American Journal of Gastroenterology 2000;95: 2218-24.
17. Morgan G. Aspirin for the primary prevention of vascular events? Public Health 2009;123:787-8.
18. McQuaid KR and Laine L. Systematic review and metaanalysis of adverse events of low-dose aspirin and Clopidogrel in randomized controlled trials. American Journal of Medicine 2006; 119:624-38. (Pubitemid 44128438)
19. JT Cohen and PJ Neumann. What's more dangerous, your aspirin or your car? Thinking rationally about drug risks (and benefits). Health Affairs 2007;26:636-46.
20. Balakrishnan S and Jhaj R. Prophylactic use of gastroprotective agents in patients on low-dose aspirin. British Journal of Clinical Pharmacology 2008;65:621-2. (Pubitemid 351365142)
21. Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT and Chiu PW. Continuation of low-dose aspirin therapy in peptic ulcer bleeding. A randomised trial. Annals of Internal Medicine 2010;152:1-9.
22. Elwood P and Longley M. My health: whose responsibility? The case of aspirin. Journal of Epidemiology and Community Health 2010;64:761-4.
23. Elwood P, Morgan G, White J et al. Aspirin taking in a south Wales county. British Journal of Cardiology (in press).
24. Cayla G, Collet JP, Silvain J, Thiefin G, Woimant F and Montalescot G. Prevalence and clinical impact of upper gastrointestinal symptoms in subjects treated with low dose aspirin: the UGLA survey. International Journal of Cardiology 17 November 2010 (epub ahead of print).